Bicocca Open Archive

Logo unimib boa
COLOMBO, NICOLETTA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 26.350
AS - Asia 17.752
EU - Europa 10.426
SA - Sud America 3.132
AF - Africa 286
OC - Oceania 51
Continente sconosciuto - Info sul continente non disponibili 29
AN - Antartide 1
Totale 58.027
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 25.752
SG - Singapore 5.516
CN - Cina 3.856
HK - Hong Kong 3.627
VN - Vietnam 2.932
RU - Federazione Russa 2.555
BR - Brasile 2.516
IT - Italia 1.752
IE - Irlanda 1.383
UA - Ucraina 1.057
SE - Svezia 983
DE - Germania 783
GB - Regno Unito 574
CA - Canada 442
KR - Corea 397
FI - Finlandia 336
ID - Indonesia 321
AT - Austria 274
AR - Argentina 262
IN - India 239
FR - Francia 184
NL - Olanda 180
JP - Giappone 154
BD - Bangladesh 146
ZA - Sudafrica 129
EC - Ecuador 124
TR - Turchia 124
MX - Messico 117
IQ - Iraq 89
DK - Danimarca 61
ES - Italia 59
PY - Paraguay 47
CO - Colombia 45
VE - Venezuela 44
AU - Australia 42
PK - Pakistan 41
MA - Marocco 40
UZ - Uzbekistan 39
CL - Cile 38
PL - Polonia 36
SA - Arabia Saudita 34
KE - Kenya 32
TW - Taiwan 31
BE - Belgio 30
EG - Egitto 27
IR - Iran 25
PE - Perù 24
RO - Romania 24
UY - Uruguay 22
EU - Europa 20
CH - Svizzera 19
AE - Emirati Arabi Uniti 18
BG - Bulgaria 16
IL - Israele 16
JO - Giordania 15
LT - Lituania 15
PT - Portogallo 15
CZ - Repubblica Ceca 14
NP - Nepal 14
TN - Tunisia 14
DZ - Algeria 13
LB - Libano 13
MY - Malesia 13
AZ - Azerbaigian 12
PH - Filippine 12
GR - Grecia 11
RS - Serbia 11
KZ - Kazakistan 10
TH - Thailandia 9
NO - Norvegia 8
QA - Qatar 8
A2 - ???statistics.table.value.countryCode.A2??? 7
AL - Albania 7
BO - Bolivia 7
DO - Repubblica Dominicana 7
MD - Moldavia 7
NZ - Nuova Zelanda 7
OM - Oman 7
SN - Senegal 7
JM - Giamaica 6
KG - Kirghizistan 6
MK - Macedonia 6
BY - Bielorussia 5
HU - Ungheria 5
PS - Palestinian Territory 5
TT - Trinidad e Tobago 5
CR - Costa Rica 4
MU - Mauritius 4
SY - Repubblica araba siriana 4
BA - Bosnia-Erzegovina 3
ET - Etiopia 3
GT - Guatemala 3
HN - Honduras 3
HR - Croazia 3
LU - Lussemburgo 3
NG - Nigeria 3
NI - Nicaragua 3
AO - Angola 2
BB - Barbados 2
BH - Bahrain 2
Totale 57.977
Salva come PNG Salva come JPEG
Città #
Hong Kong 3.605
Ann Arbor 3.338
Singapore 3.016
Woodbridge 2.684
Fairfield 2.357
Houston 1.901
Ashburn 1.524
Dublin 1.301
Jacksonville 1.196
Wilmington 1.023
Ho Chi Minh City 937
Seattle 896
Hefei 866
Cambridge 787
Dearborn 736
Chandler 695
New York 682
Hanoi 663
Princeton 639
Santa Clara 466
Milan 434
Seoul 371
Dallas 362
Beijing 337
Los Angeles 329
Lawrence 315
Moscow 306
Altamura 290
The Dalles 288
Frankfurt am Main 285
Nanjing 280
Chicago 263
Jakarta 246
São Paulo 205
Lachine 202
Vienna 197
Buffalo 175
Guangzhou 165
San Diego 143
Shanghai 136
Nuremberg 134
Andover 125
Boardman 123
Haiphong 117
London 109
Toronto 104
Dong Ket 96
Rome 92
Nanchang 87
Council Bluffs 84
Rio de Janeiro 81
Da Nang 76
Tokyo 76
Hamburg 75
Shenyang 75
Salt Lake City 70
Tianjin 70
Changsha 69
Falls Church 69
Biên Hòa 68
Helsinki 67
Hebei 60
Quận Bình Thạnh 59
Ha Long 58
Ottawa 57
Norwalk 53
Johannesburg 49
Mountain View 49
Hải Dương 48
Hangzhou 47
Ninh Bình 47
Tampa 47
Columbus 46
Guayaquil 46
Elk Grove Village 45
Jiaxing 45
Lappeenranta 45
Curitiba 44
Jinan 43
Brasília 42
Thái Nguyên 42
Dhaka 41
Redmond 41
Kent 40
Quito 40
Can Tho 39
Tashkent 39
Huizen 38
Belo Horizonte 37
Porto Alegre 37
Munich 36
Zhengzhou 35
Mexico City 34
Amsterdam 33
Bắc Ninh 32
Phoenix 32
Fremont 31
Salvador 31
Kunming 30
Quận Một 30
Totale 38.156
Salva come PNG Salva come JPEG
Nome #
ESMO-ESGO-ESTRO consensus conference on endometrial cancer: Diagnosis, treatment and follow-up 577
Single-Agent Trabectedin Versus Physician's Choice Chemotherapy in Patients With Recurrent Ovarian Cancer With BRCA -Mutated and/or BRCAness Phenotype: A Randomized Phase III Trial 566
High-dose epirubicin in patients with advanced or recurrent uterine sarcoma 544
Early CAR- CD4+ T-lymphocytes recovery following CAR-T cell infusion: A worse outcome in diffuse large B cell lymphoma 387
Erratum: Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (Annals of Oncology (2017) 28 (iv72-iv83) DOI: 10.1093/annonc/mdx220) 329
Adding immunotherapy to first-line treatment of advanced and metastatic endometrial cancer 320
Early-stage clear cell ovarian cancer compared to high-grade histological subtypes: An outcome exploratory analysis in two oncology centers 309
Harmonising clinical trials within the Gynecologic Cancer InterGroup: Consensus and unmet needs from the Fifth Ovarian Cancer Consensus Conference 306
Patient-reported outcomes and final overall survival results from the randomized phase 3 PENELOPE trial evaluating pertuzumab in low tumor human epidermal growth factor receptor 3 (HER3) mRNA-expressing platinum-resistant ovarian cancer 294
Long-term results of fertility-sparing treatment compared with standard radical surgery for early-stage epithelial ovarian cancer 281
ESMO-ESGO consensus conference recommendations on ovarian cancer: Pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease 281
CD73 Regulates Stemness and Epithelial-Mesenchymal Transition in Ovarian Cancer-Initiating Cells 274
Randomized phase III clinical trial evaluating weekly cisplatin for advanced epithelial ovarian cancer 257
Multicenter, randomised, open-label, non-comparative phase 2 trial on the efficacy and safety of the combination of bevacizumab and trabectedin with or without carboplatin in women with partially platinum-sensitive recurrent ovarian cancer 243
Conservative management of early-stage epithelial ovarian cancer: results of a large retrospective series 241
Pre-operative evaluation of epithelial ovarian cancer patients: Role of whole body diffusion weighted imaging MR and CT scans in the selection of patients suitable for primary debulking surgery. A single-centre study 241
FORWARD I: A Phase III study of mirvetuximab soravtansine versus chemotherapy in platinum-resistant ovarian cancer 238
ESMO-ESGO consensus conference recommendations on ovarian cancer: Pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease 235
Efficacy and Safety of Mirvetuximab Soravtansine in Patients With Platinum-Resistant Ovarian Cancer With High Folate Receptor Alpha Expression: Results From the SORAYA Study 221
Abagovomab as maintenance therapy in patients with epithelial ovarian cancer: A phase III trial of the AGO OVAR, COGI, GINECO, and GEICO-the MIMOSA study 221
Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: The ICON3 randomised trial 221
Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation 218
Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up 216
Early tumor regrowth is a contributor to impaired survival in patients with completely resected advanced ovarian cancer. An exploratory analysis of the Intergroup trial AGO-OVAR 12 215
The Total Neuropathy Score as an assessment tool for grading the course of chemotherapy-induced peripheral neurotoxicity: comparison with the National Cancer Institute-Common Toxicity Scale 211
Long-term follow-up of patients with an isolated ovarian recurrence after conservative treatment of epithelial ovarian cancer: review of the results of an international multicenter study comprising 545 patients 201
Endometrial cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up 200
Ultrasonographic diagnosis and longitudinal follow-up of recurrences after conservative surgery for borderline ovarian tumors 198
The disposition of carboplatin in ovarian cancer patients 197
Consensus statements and treatment algorithm to guide clinicians in the selection of maintenance therapy for patients with newly diagnosed, advanced ovarian carcinoma: Results of a Delphi study 196
A phase II randomised clinical trial comparing cisplatin, paclitaxel and ifosfamide with cisplatin, paclitaxel and epirubicin in newly diagnosed advanced epithelial ovarian cancer: long-term survival analysis 194
A Large, Multicenter, Retrospective Study on Efficacy and Safety of Stereotactic Body Radiotherapy (SBRT) in Oligometastatic Ovarian Cancer (MITO RT1 Study): A Collaboration of MITO, AIRO GYN, and MaNGO Groups 194
Diffusion-weighted MR imaging in assessing cervical tumour response to nonsurgical therapy 193
Final results from GCIG/ENGOT/AGO-OVAR 12, a randomised placebo-controlled phase III trial of nintedanib combined with chemotherapy for newly diagnosed advanced ovarian cancer 193
Randomized trial of neoadjuvant chemotherapy comparing paclitaxel, ifosfamide, and cisplatin with ifosfamide and cisplatin followed by radical surgery in patients with locally advanced squamous cell cervical carcinoma: the SNAP01 (Studio Neo-Adjuvante Portio) Italian Collaborative Study 192
Effect of a streptococcal preparation (OK432) on natural killer activity of tumour-associated lymphoid cells in human ovarian carcinoma and on lysis of fresh ovarian tumour cells 191
Hexamethylmelamine, adriamycin, and cyclophosphamide (HAC) versus cis-dichlorodiamineplatinum, adriamycin, and cyclophosphamide (PAC) in advanced ovarian cancer: a randomized clinical trial 191
Robotic Versus Open Radical Hysterectomy in Women With Locally Advanced Cervical Cancer After Neoadjuvant Chemotherapy: A Single-institution Experience of Surgical and Oncologic Outcomes 191
Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial 191
Lack of activity of cyclophosphamide in ovarian cancer patients refractory to cis-dichlorodiammine platinum 190
Neoadjuvant chemotherapy in cervical cancer: An update 190
Clinical benefit and risk of death with endocrine therapy in ovarian cancer: A comprehensive review and meta-analysis 190
Prognostic relevance of uncommon ovarian histology in women with stage III/IV epithelial ovarian cancer 189
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): A randomised, double-blind, placebo-controlled, phase 3 trial 188
Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: A phase III trial of the gynecologic cancer intergroup 187
Low-dose oral etoposide in epithelial cancer of the ovary 187
Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up 187
Homologous recombination deficiency in ovarian cancer: Global expert consensus on testing and a comparison of companion diagnostics 185
Grading of chemotherapy-induced peripheral neurotoxicity using the Total Neuropathy Scale 185
A reassessment of the role of second-look laparotomy in advanced ovarian cancer 185
Platinum-based neoadjuvant chemotherapy followed by radical surgery for cervical carcinoma international federation of gynecology and obstetrics stage IB2-IIB 184
Chemo-conization in early cervical cancer 183
Peripheral neurotoxicity of taxol in patients previously treated with cisplatin 183
Reply to M.L. Friedlander et al 183
Recommendations for the implementation of BRCA testing in ovarian cancer patients and their relatives 183
European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion 182
DR antigen expression on ovarian carcinoma cells does not correlate with their capacity to elicit an autologous proliferative response 182
Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer 182
Risk-reducing salpingo-oophorectomy in women at higher risk of ovarian and breast cancer: A single institution prospective series 181
Phase 2 study evaluating intermittent and continuous linsitinib and weekly paclitaxel in patients with recurrent platinum resistant ovarian epithelial cancer 181
An open-label phase 2 study of twice-weekly bortezomib and intermittent pegylated liposomal doxorubicin in patients with ovarian cancer failing platinum-containing regimens 180
Aggressive angiomyxoma of the vulva 179
The role of surgery in gestational trophoblastic disease 179
Overall survival results of AGO-OVAR16: A phase 3 study of maintenance pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced ovarian cancer 179
A phase III, randomized, double blinded trial of platinum based chemotherapy with or without atezolizumab followed by niraparib maintenance with or without atezolizumab in patients with recurrent ovarian, tubal, or peritoneal cancer and platinum treatment free interval of more than 6 months: ENGOT-Ov41/GEICO 69-O/ANITA Trial 179
Analysis of gene expression identifies PLAB as a mediator of the apoptotic activity of fenretinide in human ovarian cancer cells 178
Trabectedin as single agent in relapsed advanced ovarian cancer: Results from a retrospective pooled analysis of three phase II trials 178
Neoadjuvant chemotherapy prior to pelvic exenteration in patients with recurrent cervical cancer: Single institution experience 177
Recommendations for the implementation of BRCA testing in the care and treatment pathways of ovarian cancer patients 177
BRCA1/2 molecular assay for ovarian cancer patients: A survey through Italian departments of oncology and molecular and genomic diagnostic laboratories 177
Tumor-derived chemotactic factor(s) from human ovarian carcinoma: evidence for a role in the regulation of macrophage content of neoplastic tissues 176
Methotrexate with citrovorum factor in low-risk gestational trophoblastic tumor 176
Intravenous aflibercept in patients with platinum-resistant, advanced ovarian cancer: Results of a randomized, double-blind, phase 2, parallel-arm study 176
Antibody-dependent and -independent cytotoxicity of human mononuclear phagocytes: defective stimulation of tumoricidal activity in milk macrophages 176
Defective natural killer activity within human ovarian tumors: Low numbers of morphologically defined effectors present in situ 175
Surgical management of malignant ovarian germ-cell tumors: 10 years' experience of 129 patients 175
Pure ovarian immature teratoma, a unique and curable disease: 10 years' experience of 32 prospectively treated patients 175
Phase II study of carboplatin in recurrent ovarian cancer: severe hematologic toxicity in previously treated patients 175
Outcome according to residual disease (surgeon's report vs pre-chemotherapy imaging) in patients with bevacizumab-treated ovarian cancer: Analysis of the ROSiA study 174
Early oral versus "traditional" postoperative feeding in gynecologic oncology patients undergoing intestinal resection: A randomized controlled trial 173
Cisplatin, vinblastine, and bleomycin combination chemotherapy in metastatic granulosa cell tumor of the ovary 173
Feasibility and outcome of interval debulking surgery (IDS) after carboplatin-paclitaxel-bevacizumab (CPB): A subgroup analysis of the MITO-16A-MaNGO OV2A phase 4 trial 173
Robotic Surgery: Changing the Surgical Approach for Endometrial Cancer in a Referral Cancer Center 172
Treatment of advanced ovarian cancer (OC): A randomized trial comparing different platinum (P) combinations 172
Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer delays third-line chemotherapy and prolongs the platinum-free interval 171
Experience with trabectedin + pegylated liposomal doxorubicin for recurrent platinum-sensitive ovarian cancer unsuited to platinum rechallenge 171
A phase II, randomized trial of neo-adjuvant chemotherapy comparing a three-drug combination of paclitaxel, ifosfamide, and cisplatin (TIP) versus paclitaxel and cisplatin (TP) followed by radical surgery in patients with locally advanced squamous cell cervical carcinoma: the Snap-02 Italian Collaborative Study 171
Early predictors of peripheral neurotoxicity in cisplatin and paclitaxel combination chemotherapy 170
Adjuvant chemotherapy in stage I-II uterine leiomyosarcoma: a multicentric retrospective study of 140 patients 170
Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: A randomised phase 2 trial 170
Hexamethylmelamine-CAF (cyclophosphamide, methotrexate, and 5-FU) and cisplatin-CAF in refractory ovarian cancer 169
Parp inhibitors as maintenance treatment in platinum sensitive recurrent ovarian cancer: An updated meta-analysis of randomized clinical trials according to BRCA mutational status 169
Pre-chemotherapy hemoglobin levels and survival in patients with advanced epithelial ovarian cancer who received a first-line taxane/platinum-based regimen: Results of a multicenter retrospective Italian study 167
Optimal treatment of early-stage ovarian cancer 167
Next-generation sequencing-based BRCA testing on cytological specimens from ovarian cancer ascites reveals high concordance with tumour tissue analysis 167
Hydrological, thermal and chemical influence of an intact rock glacier discharge on mountain stream water 166
International Collaborative Ovarian Neoplasm trial 1: a randomized trial of adjuvant chemotherapy in women with early-stage ovarian cancer 166
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial 165
External validation of a prognostic nomogram for overall survival in women with uterine leiomyosarcoma 164
Optimizing treatment of the partially platinum-sensitive ovarian cancer patient 163
Totale 20.965
Salva come PNG Salva come JPEG
Categoria #
all - tutte 215.964
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 215.964
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20212.786 0 0 0 0 0 396 481 511 396 478 199 325
2021/20223.002 181 245 348 237 184 196 168 209 186 250 231 567
2022/20234.033 665 1.028 274 226 247 729 59 327 243 66 95 74
2023/20244.164 98 105 176 111 637 1.033 755 107 525 117 68 432
2024/202513.024 713 1.688 492 616 1.039 526 998 405 1.286 1.616 1.088 2.557
2025/202615.404 3.666 3.062 2.373 3.235 2.689 379 0 0 0 0 0 0
Totale 59.458